자유게시판

• 목록
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision regarding whether or not to stop taking ADHD medication during pregnancy and breastfeeding. There aren't enough data on how long-term exposure may affect the fetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to Private adhd assessment Medway medication during pregnancy do not develop neurological issues such as impaired hearing or vision, febrile seizures or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medications need to balance the advantages of taking them against the potential risks to the fetus. Physicians do not have the necessary data to give clear guidelines but they can provide information on the risks and benefits to help pregnant women make informed choices.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during early pregnancy did not have a greater risk of fetal malformations or structural birth defects. Researchers conducted a large population-based study of case control to compare the incidence of structural defects that were major in infants who were born to mothers who took stimulants during pregnancy. Clinical geneticists, pediatric cardiologists and other experts examined the cases to confirm that the classification was correct and to reduce any bias.

The study of the researchers had some limitations. In particular, they were unable to separate the effects of the medication from the effects of the disorder that is underlying. This limitation makes it difficult to determine whether the small differences observed in the exposed groups result from medication use or comorbidities that cause confusion. Researchers also did not examine the long-term effects for the offspring.

The study found that infants whose mother had taken ADHD medication during pregnancy had a greater risk of being admitted to the neonatal care unit (NICU) as compared to those whose mothers did not take any medication during pregnancy, or had stopped taking their medication before or during pregnancy. This was due to central nervous system disorders, and the higher risk of admission did not appear to be influenced by which stimulant medications were taken during pregnancy.

Women who were taking stimulant ADHD medication during pregnancy also had an increased chance of having a caesarean section or having a child with a low Apgar score (less than 7). These increases appear to be independent of the type of medication taken during pregnancy.

The research suggests that the low risk associated with the use of ADHD medications during early pregnancy could be offset by the greater benefits for both mother and child from continued treatment for the woman's disorder. Physicians should discuss the issue with their patients and, when possible, help them develop strategies for improving their coping skills that can lessen the effects of her disorder on her daily life and relationships.

Medication Interactions

As more women than ever are being diagnosed with ADHD and treated with medication, the issue of whether to continue or stop treatment during pregnancy is one that more and more doctors confront. The majority of these decisions are made without solid and reliable evidence in either case, which means that doctors must weigh what they know about their experiences, the experiences of other doctors, and what the research says on the topic as well as their best judgment for each individual patient.

The issue of possible risks for infants can be particularly tricky. Many of the studies on this issue are based on observations rather than controlled research and their findings are often contradictory. The majority of studies focus on live-births, which could underestimate the severity of teratogenic effects which can cause abortions or terminations of pregnancy. The study that is discussed in the journal club addresses these shortcomings, by examining both information on deceased and live births.

Conclusion Some studies have found a positive correlation between ADHD medications and certain birth defects, other studies have not found a correlation. The majority of studies show a neutral, or even somewhat negative, impact. As a result an accurate risk-benefit analysis must be conducted in every case.

For women suffering from ADHD, the decision to discontinue medication for inattentive adhd is difficult, if not impossible. In a recent article in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping adhd medication making it worse medications during pregnancy can increase depression and feelings of loneliness. Additionally, the loss of medication can interfere with the ability to do work-related tasks and safely drive, which are important aspects of daily life for many people suffering from ADHD.

She suggests that women who are unsure whether to take the medication or discontinue it due to pregnancy should educate family members, coworkers, and acquaintances about the condition, its effects on daily functioning, and the advantages of staying on the current treatment. Educating them can also make the woman feel more comfortable when she is struggling with her decision. Some medications can pass through the placenta. If a woman decides to stop taking her ADHD medication while pregnant and breastfeeding, it's important to be aware that the medication may be transferred to her baby.

Risk of Birth Defects

As the use and use of adhd medications for adults drugs to treat symptoms of attention deficit disorder hyperactivity disorder (ADHD) is increasing the concern over the possible effects of the drugs on fetuses. A recent study published in the journal Molecular Psychiatry adds to the body of knowledge about this subject. Researchers used two huge data sets to study more than 4.3 million pregnant women and determine if the use of stimulant medications increased birth defects. Researchers discovered that, while the overall risk is low, the first trimester ADHD exposure to medication was associated with slightly higher risk of certain heart defects, like ventriculoseptal defect.

The authors of the study could not discover any link between early medication usage and congenital anomalies such as facial deformities or club feet. The results are in the same vein as previous studies which showed an insignificant, but small increase in cardiac malformations for women who started taking ADHD medication prior to the time of the birth of their child. This risk increased in the later part of pregnancy, as many women begin to discontinue their ADHD medication.

Women who were taking ADHD medication in the first trimester were more likely to require a caesarean birth and also have an insufficient Apgar after delivery and had a baby that required help breathing when they were born. The authors of the study could not eliminate bias due to selection because they limited the study to women who did not have any other medical conditions that might have contributed to the findings.

The researchers hope their study will aid in the clinical decisions of doctors who treat pregnant women. They recommend that, while a discussion of the risks and benefits is crucial however, the decision to stop or maintain medication should be based on the woman's requirements and the severity of her ADHD symptoms.

The authors also caution that even though stopping the medication is an alternative, it is not an option to consider due to the high prevalence of depression and other mental health problems among women who are pregnant or post-partum. Additionally, the research suggests that women who decide to stop taking their medication are more likely to experience difficulties getting used to life without them following the baby's arrival.

Nursing

It can be a challenge becoming a mother. Women with ADHD who must work through their symptoms while attending doctor appointments and preparing for the arrival of their child and getting used to new routines at home may face a lot of challenges. Therefore, many women choose to continue taking their ADHD medications throughout pregnancy.

The risk to nursing infant is low because the majority of stimulant medications is absorbed through breast milk at a low level. The rate of medication exposure will vary based on the dosage, frequency of administration and time of day. In addition, various drugs enter the infant's system through the gastrointestinal tract or breast milk. The impact of these medications on the health of a newborn is not fully comprehended.

Because of the lack of research, some physicians might be tempted to stop taking stimulant drugs during a woman's pregnancy. This is a difficult decision for the patient, who must weigh the benefits of keeping her medication against the potential risks to the fetus. In the meantime, until more information is available, doctors may inquire about pregnant patients whether they have a background of adhd treatment medication or if they intend to take medication during the perinatal stage.

A growing number of studies have shown that women can continue to take their ADHD medication during pregnancy and while breastfeeding. In response, a growing number of patients are choosing to do this. They have found, in consultation with their doctor that the benefits of keeping their current medication far outweigh any risk.

Women with ADHD who are planning to nurse should seek advice from a specialist psychiatrist prior to becoming pregnant. They should review their medications with their physician and discuss the advantages and disadvantages of continued treatment, including non-pharmacological management strategies. Psychoeducation is also needed to help pregnant women with ADHD understand the symptoms and the underlying disorder. They should also be informed about treatment options and reinforce strategies for coping. This should be a multidisciplinary approach together with obstetricians, GPs and psychiatry. Pregnancy counselling should include discussion of a management plan for both the mother as well as the child, as well as monitoring for signs of deterioration and the need for adjustments to the medication regimen.